DaVita Inc. $DVA Shares Sold by Berkshire Hathaway Inc

Berkshire Hathaway Inc cut its stake in DaVita Inc. (NYSE:DVA) by 4.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 32,160,579 shares of the company’s stock after selling 1,635,962 shares during the period. DaVita accounts for approximately 1.6% of Berkshire Hathaway Inc’s holdings, making the stock its 11th largest holding. Berkshire Hathaway Inc owned approximately 0.46% of DaVita worth $4,273,176,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DVA. Arrowstreet Capital Limited Partnership lifted its position in DaVita by 109.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after purchasing an additional 289,725 shares during the period. Man Group plc raised its stake in shares of DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after buying an additional 269,081 shares in the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after buying an additional 269,015 shares during the period. Norges Bank bought a new position in DaVita during the second quarter valued at about $32,986,000. Finally, Todd Asset Management LLC acquired a new position in DaVita during the third quarter worth about $21,842,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 1.6%

NYSE:DVA opened at $150.67 on Friday. The stock has a fifty day simple moving average of $131.81 and a 200 day simple moving average of $127.09. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 0.53 and a beta of 0.94. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $159.42.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the previous year, the company earned $2.24 EPS. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Equities analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on DVA. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Barclays boosted their target price on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. UBS Group raised their target price on shares of DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Finally, Truist Financial set a $158.00 price target on shares of DaVita in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.